Veracyte, Inc. (VCYT) stock
VCYTNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 16/3034% below fair value
$24.23+0.22 (+0.92%)
Close on Nov 17, 2026Market cap $1.95BP/E 17.3Yield –
Veracyte EV/EBITDA
EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.
Veracyte's EV/EBITDA was 13.6× on Nov 11, 2026, against 72.7× a year earlier.
EV/EBITDA at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 13.6× | −50.3 |
| 2025 | Dec 31, 2025 | 63.9× | – |
See a number that looks wrong?